Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update

In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Qin, Chenman, Fei, Yunyun, Shen, Min, Zhou, Yangzhong, Zhang, Yan, Zeng, Xiaofeng, Zhang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040414/
https://www.ncbi.nlm.nih.gov/pubmed/35477027
http://dx.doi.org/10.1016/j.clim.2022.109022
_version_ 1784694330355613696
author Zhang, Wen
Qin, Chenman
Fei, Yunyun
Shen, Min
Zhou, Yangzhong
Zhang, Yan
Zeng, Xiaofeng
Zhang, Shuyang
author_facet Zhang, Wen
Qin, Chenman
Fei, Yunyun
Shen, Min
Zhou, Yangzhong
Zhang, Yan
Zeng, Xiaofeng
Zhang, Shuyang
author_sort Zhang, Wen
collection PubMed
description In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine.
format Online
Article
Text
id pubmed-9040414
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-90404142022-04-26 Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update Zhang, Wen Qin, Chenman Fei, Yunyun Shen, Min Zhou, Yangzhong Zhang, Yan Zeng, Xiaofeng Zhang, Shuyang Clin Immunol Review Article In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine. Published by Elsevier Inc. 2022-06 2022-04-25 /pmc/articles/PMC9040414/ /pubmed/35477027 http://dx.doi.org/10.1016/j.clim.2022.109022 Text en © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Zhang, Wen
Qin, Chenman
Fei, Yunyun
Shen, Min
Zhou, Yangzhong
Zhang, Yan
Zeng, Xiaofeng
Zhang, Shuyang
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title_full Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title_fullStr Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title_full_unstemmed Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title_short Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
title_sort anti-inflammatory and immune therapy in severe coronavirus disease 2019 (covid-19) patients: an update
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040414/
https://www.ncbi.nlm.nih.gov/pubmed/35477027
http://dx.doi.org/10.1016/j.clim.2022.109022
work_keys_str_mv AT zhangwen antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT qinchenman antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT feiyunyun antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT shenmin antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT zhouyangzhong antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT zhangyan antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT zengxiaofeng antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate
AT zhangshuyang antiinflammatoryandimmunetherapyinseverecoronavirusdisease2019covid19patientsanupdate

Ejemplares similares